- Home
- DSM vs VNDA Comparison
DSM vs VNDA Comparison
Compare DSM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- VNDA
- Stock Information
- Founded
- DSM 1989
- VNDA 2002
- Country
- DSM United States
- VNDA United States
- Employees
- DSM N/A
- VNDA N/A
- Industry
- DSM Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- VNDA Health Care
- Exchange
- DSM Nasdaq
- VNDA Nasdaq
- Market Cap
- DSM 270.9M
- VNDA 237.9M
- IPO Year
- DSM N/A
- VNDA 2006
- Fundamental
- Price
- DSM $5.74
- VNDA $4.22
- Analyst Decision
- DSM
- VNDA Strong Buy
- Analyst Count
- DSM 0
- VNDA 2
- Target Price
- DSM N/A
- VNDA $16.50
- AVG Volume (30 Days)
- DSM 161.7K
- VNDA 500.0K
- Earning Date
- DSM 01-01-0001
- VNDA 05-07-2025
- Dividend Yield
- DSM 3.97%
- VNDA N/A
- EPS Growth
- DSM N/A
- VNDA N/A
- EPS
- DSM N/A
- VNDA N/A
- Revenue
- DSM N/A
- VNDA $201,351,000.00
- Revenue This Year
- DSM N/A
- VNDA $14.36
- Revenue Next Year
- DSM N/A
- VNDA $44.53
- P/E Ratio
- DSM N/A
- VNDA N/A
- Revenue Growth
- DSM N/A
- VNDA 13.37
- 52 Week Low
- DSM $4.69
- VNDA $3.85
- 52 Week High
- DSM $6.05
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- DSM 59.21
- VNDA 41.17
- Support Level
- DSM $5.63
- VNDA $4.20
- Resistance Level
- DSM $5.75
- VNDA $4.64
- Average True Range (ATR)
- DSM 0.07
- VNDA 0.17
- MACD
- DSM 0.04
- VNDA 0.01
- Stochastic Oscillator
- DSM 97.22
- VNDA 20.75
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.